CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

CASI Pharmaceuticals Inc.

CASI Pharmaceuticals ( ($CASI) ) has shared an update. On November 19, 2025, CASI Pharmaceuticals announced a significant change in its board gover...

CASI Pharmaceuticals Appoints James Huang as Non-Executive Chairman

An update from CASI Pharmaceuticals ( ($CASI) ) is now available. On November 14, 2025, CASI Pharmaceuticals announced its third-quarter 2025 busin...

Market Cap	$18.75M	P/E Ratio	N/A
52W High	$5.14	52W Low	$1.09
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	1.6%	52W Position	3.4%
Overall Score	18	Value Score	--
Quality Score	--	Technical Score	18

EPS Current Est	$-2.31	EPS Next Est	$-1.45
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CASI	$1.23	+3.36%	22.29K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CASI	$1.23	+3.4%	22.29K
3
4
5
6

CASI

CASI

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get CASI Pharmaceuticals Inc. Data in Excel

Get CASI Pharmaceuticals Inc. Data in Excel